[1]谭婕 徐书杭.IL-6受体及其受体抗体在Graves眼病中的作用研究进展[J].国际内分泌代谢杂志,2023,43(05):380-383.[doi:10.3760/cma.j.cn121383-20220731-07068]
　Tan Jie,Xu Shuhang..Update of interleukin-6 receptor and its antibody's role in Graves' orbitopathy[J].International Journal of Endocrinology and Metabolism,2023,43(05):380-383.[doi:10.3760/cma.j.cn121383-20220731-07068]
点击复制

IL-6受体及其受体抗体在Graves眼病中的作用研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年05期
页码:
380-383
栏目:
综述
出版日期:
2023-09-20

文章信息/Info

Title:
Update of interleukin-6 receptor and its antibody's role in Graves' orbitopathy
作者:
谭婕 徐书杭
南京中医药大学附属中西医结合医院内分泌科,南京 210028
Author(s):
Tan Jie;  Xu Shuhang.
Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China
关键词:
Graves眼病;  白细胞介素-6;  白细胞介素-6受体;  托珠单抗
Keywords:
Graves' orbitopathy;  Interleukin-6;  Interleukin-6 receptor;  Tocilizumab
DOI:
10.3760/cma.j.cn121383-20220731-07068
摘要:
Graves眼病(Graves' orbitopathy,GO)是Graves病(Graves'disease,GD)的主要甲状腺外表现。中度至重度GO是治疗的主要挑战,因其通常对现有的药物治疗反应不完全。糖皮质激素是中重度活动性GO的一线治疗方案,但有不少GO患者存在糖皮质激素治疗抵抗。研究已表明,白细胞介素(IL)-6受体参与了GO的发展。作为一种直接针对IL-6的重组人源化单克隆抗体,托珠单抗在临床研究中被证实对中到重度糖皮质激素抵抗的GO患者确有疗效,这表明靶向阻断IL-6受体的药物未来可能在GO治疗中占有一席之地。
Abstract:
Graves'orbitopathy(GO)is the main extrathyroidal manifestation of Graves'disease(GD). GO is a major therapeutic challenge in its moderate-to-severe forms, often incompletely responsive to available medical treatments. Glucocorticoids are the first-line treatment for moderate to severe active Graves' orbitopathy(GO), but a certain amount of GO patients are still refractory to glucocorticoids treatment. Previous research have found that IL-6R participates in the development of GO. As a recombinant humanized monoclonal antibody directed against the IL-6 receptor, TCZ has shown its efficacy in moderate to severe glucocorticoid resistant GO patients. Therefore, drugs targeting IL-6R may claim its place in GO treatment someday.

参考文献/References:

[1] Bartalena L,Kahaly GJ,Baldeschi L,et al.The 2021 European Group on Graves' orbitopathy(EUGOGO)clinical practice guidelines for the medical management of Graves' orbitopathy[J].Eur J Endocrinol,2021,185(4):G43-G67.DOI:10.1530/EJE-21-0479.
[2] Hunter CA,Jones SA.IL-6 as a keystone cytokine in health and disease[J].Nat Immunol,2015,16(5):448-457.DOI:10.1038/ni.3153.
[3] Jones SA,Jenkins BJ.Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer[J].Nat Rev Immunol,2018,18(12):773-789.DOI:10.1038/s41577-018-0066-7.
[4] Salvi M,Girasole G,Pedrazzoni M,et al.Increased serum concentrations of interleukin-6(IL-6)and soluble IL-6 receptor in patients with Graves' disease[J].J Clin Endocrinol Metab,1996,81(8):2976-2979.DOI:10.1210/jcem.81.8.8768861.
[5] Wahrenberg H,Wennlund A,Hoffstedt J.Increased adipose tissue secretion of interleukin-6,but not of leptin,plasminogen activator inhibitor-1 or tumour necrosis factor alpha,in Graves' hyperthyroidism[J].Eur J Endocrinol,2002,146(5):607-611.DOI:10.1530/eje.0.1460607.
[6] Leszczynska A,Molins B,Fernández E,et al.Cytokine production in thyroid eye disease: in vitro effects of dexamethasone and IL-6 blockade with tocilizumab[J].Graefes Arch Clin Exp Ophthalmol,2019,257(10):2307-2314.DOI:10.1007/s00417-019-04419-7.
[7] Bahn RS.Graves' ophthalmopathy[J].N Engl J Med,2010,362(8):726-738.DOI:10.1056/NEJMra0905750.
[8] Lee ACH,Kahaly GJ.Pathophysiology of thyroid-associated orbitopathy[J].Best Pract Res Clin Endocrinol Metab,2023,37(2):101620.DOI:10.1016/j.beem.2022.101620.
[9] Anvari M,Khalilzadeh O,Esteghamati A,et al.Graves' disease and gene polymorphism of TNF-α,IL-2,IL-6,IL-12,and IFN-γ[J].Endocrine,2010,37(2):344-348.DOI:10.1007/s12020-010-9311-y.
[10] Hiromatsu Y,Yang D,Bednarczuk T,et al.Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy[J].J Clin Endocrinol Metab,2000,85(3):1194-1199.DOI:10.1210/jcem.85.3.6433.
[11] Kishazi E,Dor M,Eperon S,et al.Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy[J].Sci Rep,2018,8(1):10792.DOI:10.1038/s41598-018-29113-2.
[12] Dimberg J,Ström K,Löfgren S,et al.Expression of the serine protease inhibitor serpinA3 in human colorectal adenocarcinomas[J].Oncol Lett,2011,2(3):413-418.DOI:10.3892/ol.2011.280.
[13] Jyonouchi SC,Valyasevi RW,Harteneck DA,et al.Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves' ophthalmopathy[J].Thyroid,2001,11(10):929-934.DOI:10.1089/105072501753210984.
[14] Prabhakar BS,Bahn RS,Smith TJ.Current perspective on the pathogenesis of Graves' disease and ophthalmopathy[J].Endocr Rev,2003,24(6):802-835.DOI:10.1210/er.2002-0020.
[15] Smith RS,Smith TJ,Blieden TM,et al.Fibroblasts as sentinel cells.Synthesis of chemokines and regulation of inflammation[J].Am J Pathol,1997,151(2):317-322.
[16] Hamed Azzam S,Kang S,Salvi M,et al.Tocilizumab for thyroid eye disease[J].Cochrane Database Syst Rev,2018,11(11):CD012984.DOI:10.1002/14651858.CD012984.pub2.
[17] Scott LJ.Tocilizumab:a review in rheumatoid arthritis[J].Drugs,2017,77(17):1865-1879.DOI:10.1007/s40265-017-0829-7.
[18] Perez-Moreiras JV,Gomez-Reino JJ,Maneiro JR,et al.Efficacy of Tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy:a randomized clinical trial[J].Am J Ophthalmol,2018,195:181-190.DOI:10.1016/j.ajo.2018.07.038.
[19] Pérez-Moreiras JV,Varela-Agra M,Prada-Sánchez MC,et al.Steroid-resistant Graves' orbitopathy treated with Tocilizumab in real-world clinical practice:a 9-year single-center experience[J].J Clin Med,2021,10(4):706.DOI:10.3390/jcm10040706.
[20] Sánchez-Bilbao L,Martínez-López D,Revenga M,et al.Anti-IL-6 receptor Tocilizumab in refractory Graves' orbitopathy:national multicenter observational study of 48 patients[J].J Clin Med,2020,9(9):2816.DOI:10.3390/jcm9092816.
[21] Moi L,Hamedani M,Ribi C.Long-term outcomes in corticosteroid-refractory Graves' orbitopathy treated with tocilizumab[J].Clin Endocrinol(Oxf),2022,97(3):363-370.DOI:10.1111/cen.14655.
[22] Albrashdi S,Alsharqi H,Habroosh F,et al.Tocilizumab use in pediatric thyroid eye disease:first documented case[J].Am J Ophthalmol Case Rep,2022,25:101387.DOI:10.1016/j.ajoc.2022.101387.
[23] Stevens SM,Pirakitikulr N,Lee BW.Subcutaneous tocilizumab for active thyroid eye disease refractory to orbital radiation and systemic steroids in tobacco smokers[J].Taiwan J Ophthalmol,2022,12(1):39-43.DOI:10.4103/tjo.tjo_59_21.
[24] Smith LD,Moscato EE,Seiff SR.Tocilizumab for the management of Thyroid-associated orbitopathy[J].Ophthalmic Plast Reconstr Surg,2022,38(2):188-192.DOI:10.1097/IOP.0000000000002027.
[25] Dorado Cortez O,Grivet D,Perrillat N,et al.Treatment of corticosteroid-resistant Graves' orbitopathy with tocilizumab:a single-centre prospective study[J].Orbit,2022,1-7.DOI:10.1080/01676830.2022.2119262.
[26] Pampín-Sánchez R,Martínez-Mugica-Barbosa C,Fonseca-Aizpuru EM,et al.Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease[J].Med Clin(Barc),2023,160(3):113-117.DOI:10.1016/j.medcli.2022.05.007.
[27] 中华医学会内分泌学分会,中国医师协会内分泌代谢科医师分会,中华医学会核医学分会,等.中国甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南[J].国际内分泌代谢杂志,2022,42(5):401-450.DOI:10.3760/cma.j.cn311282-20220624-00404.
[28] 中华医学会眼科学分会眼整形眼眶病学组,中华医学会内分泌学分会甲状腺学组.中国甲状腺相关眼病诊断和治疗指南(2022年)[J].中华眼科杂志,2022,58(9):646-668.DOI:10.3760/cma.j.cn112142-20220421-00201.

相似文献/References:

[1]孟淑华,魏军平.TSHR信号转导通路在Graves眼病发病机制中的作用[J].国际内分泌代谢杂志,2014,(02):84.[doi:10.3760/cma.j.issn.1673-4157.2014.02.004]
　Meng Shuhua,Wei Junping..Roles of TSHR signal transduction pathway in Graves' ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2014,(05):84.[doi:10.3760/cma.j.issn.1673-4157.2014.02.004]
[2]杨薇,李春君,孙蓓,等.雷公藤多苷对糖尿病肾病大鼠核因子-κB 信号通路的影响[J].国际内分泌代谢杂志,2016,36(02):107.[doi:10.3760/cma.j.issn.1673-4157.2016.02.008]
　Yang Wei*,Li Chunjun,Sun Bei,et al.Effects of triperygium wilfordii polyglucoside on nuclear factor-κB signaling pathway in rats with diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2016,36(05):107.[doi:10.3760/cma.j.issn.1673-4157.2016.02.008]
[3]余静雯 胡欣 叶向荣 陈彦 刘超.2021年欧洲甲状腺学会/欧洲Graves眼病专家组Graves眼病管理指南:解读与思考[J].国际内分泌代谢杂志,2022,42(04):250.[doi:10.3760/cma.j.cn121383-20211003-10002]
　Yu Jingwen,Hu Xin,Ye Xiangrong,et al.Interpretation and discussion of the 2021 European Thyroid Association/European Group on Graves'Orbitopathy Guidelines for the Management of Graves' Orbitopathy[J].International Journal of Endocrinology and Metabolism,2022,42(05):250.[doi:10.3760/cma.j.cn121383-20211003-10002]

备注/Memo

备注/Memo:
通信作者:徐书杭,shuhangxu@163.com
基金项目:2020年江苏省重点研发计划(BE2020726); 江苏省卫生健康委医学科研项目(面上项目,M2020102); 中华国际医学交流基金会甲状腺中青年医生研究项目(BQE-JZX-202115)
更新日期/Last Update: 2023-10-10